CSL CEO Paul Perreault determined to grow plasma collection after full-year sales dip – Endpoints News

0
204
CSL CEO Paul Perreault determined to grow plasma collection after full-year sales dip – Endpoints News


As the ink dries on CSL’s $11.7 bil­lion Vi­for buy­out, the com­pa­ny post­ed a dip in prof­its, due in part to a drop in plas­ma do­na­tions amid the pan­dem­ic.

How­ev­er, CEO Paul Per­reault as­sured in­vestors and an­a­lysts on the full-year call that the team has left “no stone un­turned” when as­sess­ing op­tions to grow plas­ma vol­umes. The chief ex­ec­u­tive al­so spelled out pos­i­tive re­sults for the com­pa­ny’s mon­o­clon­al an­ti­body garadacimab in hered­i­tary an­gioede­ma (HAE), though he isn’t re­veal­ing the ex­act num­bers just yet.

“Garadacimab has the po­ten­tial to be an­oth­er flag­ship mol­e­cule for CSL,” Per­reault said on the call, adding in a news re­lease that garadacimab met its pri­ma­ry and sec­ondary end­points and showed “fa­vor­able safe­ty and tol­er­a­bil­i­ty.”

The com­pa­ny’s stock on the Aus­tralian Se­cu­ri­ties Ex­change was down 1.3% on Wednes­day, pric­ing at around $202.

CSL prof­its were down rough­ly 6% for the four quar­ters end­ing June 30, Per­reault re­vealed on Wednes­day. A drop in plas­ma do­na­tions in FY21 con­strained sales of the com­pa­ny’s core plas­ma ther­a­pies in FY22, giv­en the long man­u­fac­tur­ing cy­cle, he said.

“The pan­dem­ic has put us two years be­hind pro­ject­ed growth in plas­ma col­lec­tions – which is sub­op­ti­mal for pa­tient care,” Per­reault said in a news re­lease.

CSL’s plas­ma do­na­tions are used to pro­duce ther­a­pies that treat bleed­ing dis­or­ders from HAE to Von Wille­brand dis­ease. CSL’s im­munoglob­u­lin and al­bu­min fran­chis­es re­ly heav­i­ly on do­na­tions.

Though the com­pa­ny has tak­en mea­sures to grow its plas­ma col­lec­tion, that comes at a high­er cost. All in all, plas­ma col­lec­tion is up 24% over the pre­vi­ous fis­cal year, as the re­sult of 27 new plas­ma col­lec­tion cen­ters open­ing. The com­pa­ny al­so aims to launch its plasma­phere­sis plat­form in FY23, which promis­es to re­duce the av­er­age do­na­tion time by about 30%.

“I will say Covid has pre­sent­ed chal­lenges for pa­tients. They have had lim­it­ed ac­cess to treat­ment and di­ag­no­sis. There has al­so been an en­vi­ron­ment of con­strained sup­ply,” Per­reault said on the call. “As the glob­al sup­ply re­cov­ers, we are an­tic­i­pat­ing a strong growth re­bound in the Ig port­fo­lio, with op­por­tu­ni­ties in core in­di­ca­tions of pri­ma­ry im­mune de­fi­cien­cy, sec­ondary im­mune de­fi­cien­cy and CIDP.”

As for garadacimab, Per­reault said full re­sults will be pre­sent­ed at an up­com­ing con­fer­ence, and CSL hopes to be­gin fil­ing with glob­al health au­thor­i­ties by the end of the cur­rent fis­cal year.

The CEO is wait­ing un­til Oc­to­ber to re­veal more in­for­ma­tion about the in­te­gra­tion of Vi­for. The com­pa­nies re­ceived reg­u­la­to­ry clear­ance just a cou­ple of weeks ago — months af­ter ini­tial­ly an­nounc­ing the deal.



Source link